Hormone Modulators and Pct Risks
SERMs and aromatase inhibitors are prescription medicines used in cancer or fertility care. Using them as post-cycle therapy after anabolic steroids is an unapproved use that can cause serious harm.
Key takeaways
- SERMs and aromatase inhibitors alter hormone signalling in different ways and are not interchangeable.
- Symptoms after anabolic steroid use need clinical assessment rather than a self-selected hormone regimen.
- Unsupervised use can worsen hormone imbalance and affect mood, fertility, bone health, the liver or clotting risk.
Listings are for comparison only; suitability and supply depend on a clinician’s diagnosis, prescription and pharmacy checks.
How the medicine groups differ
SERMs such as clomifene and tamoxifen modify oestrogen signalling. Aromatase inhibitors such as anastrozole, letrozole and exemestane reduce oestrogen production. Their approved uses, monitoring and adverse effects differ.
What these medicines are used for
Approved medical uses may include breast cancer and selected cases of anovulatory infertility. A listing does not endorse use for bodybuilding, performance enhancement or post-cycle therapy.
Important safety checks
A clinician should know about anabolic steroid use, fertility plans, mood symptoms, liver problems, bone health, clotting history and all other medicines. Hormone blood tests need clinical interpretation; a single result does not establish a safe self-treatment plan.
When to seek urgent care
Seek urgent help for chest pain, sudden breathlessness, one-sided leg swelling, signs of stroke, severe mood changes or suicidal thoughts, yellowing of the skin or eyes, or a serious allergic reaction.